APA

Littlepage L. E., Adler A. S., Kouros-Mehr H., Huang G., Chou J., Krig S. R., Griffith O. L., Korkola J. E., Qu K., Lawson D. A., Xue Q., Sternlicht M. D., Dijkgraaf G. J. P., Yaswen P., Rugo H. S., Sweeney C. A., Collins C. C., Gray J. W., Chang H. Y. & Werb Z. (20121217). The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. : Cancer discovery.

Chicago

Littlepage Laurie E, Adler Adam S, Kouros-Mehr Hosein, Huang Guiqing, Chou Jonathan, Krig Sheryl R, Griffith Obi L, Korkola James E, Qu Kun, Lawson Devon A, Xue Qing, Sternlicht Mark D, Dijkgraaf Gerrit J P, Yaswen Paul, Rugo Hope S, Sweeney Colleen A, Collins Colin C, Gray Joe W, Chang Howard Y and Werb Zena. 20121217. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. : Cancer discovery.

Harvard

Littlepage L. E., Adler A. S., Kouros-Mehr H., Huang G., Chou J., Krig S. R., Griffith O. L., Korkola J. E., Qu K., Lawson D. A., Xue Q., Sternlicht M. D., Dijkgraaf G. J. P., Yaswen P., Rugo H. S., Sweeney C. A., Collins C. C., Gray J. W., Chang H. Y. and Werb Z. (20121217). The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. : Cancer discovery.

MLA

Littlepage Laurie E, Adler Adam S, Kouros-Mehr Hosein, Huang Guiqing, Chou Jonathan, Krig Sheryl R, Griffith Obi L, Korkola James E, Qu Kun, Lawson Devon A, Xue Qing, Sternlicht Mark D, Dijkgraaf Gerrit J P, Yaswen Paul, Rugo Hope S, Sweeney Colleen A, Collins Colin C, Gray Joe W, Chang Howard Y and Werb Zena. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. : Cancer discovery. 20121217.